← Eichor
Study identifier: NCT05490225 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Access Cannulation Trial II

Condition: Dialysis; Complications · Vascular Access Complication  ·  Sponsor: Voyager Biomedical

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.

This description comes directly from the study's public registry record.

Talk to the study team

Britnee Ochabski  ·  9493224050  ·  bochabski@voyagerbiomedical.com

Supraj Amunje  ·  samunje@voyagerbiomedical.com

Always discuss trial participation with your own doctor first.

Locations (8)

Trinity Research GroupDothan, Alabama, United StatesRecruiting
Apex ResearchRiverside, California, United StatesRecruiting
Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting
Northwell HealthHyde Park, New York, United StatesRecruiting
MUSC Health OrangeburgOrangeburg, South Carolina, United StatesRecruiting
Cardiothoracic and Vascular SurgeonsAustin, Texas, United StatesRecruiting
Baylor Scott & WhiteDallas, Texas, United StatesRecruiting
Fairlawn Surgery CenterRoanoke, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05490225